Immunologic Research

, Volume 66, Issue 2, pp 219–223 | Cite as

T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates

  • Blake M. Callahan
  • Wei Lue Tong
  • George Blanck
Original Article


T cell receptor (TCR) β V and J usage correlates with either the HLA class I or HLA class II major histocompatibility subtypes, and in both infectious diseases and autoimmune settings, the use of particular TCR-β V and J’s, in persons with specific HLA alleles, represents either better outcomes or certain clinical features. However, the relationship of TCR V and J usage, HLA alleles, and clinical parameters in the cancer setting has been less well studied. Here, we have evaluated the relationship of what is likely dominant TCR-β V and J usage among tissue-resident lymphocytes for lung, head and neck, kidney, stomach, ovarian, and endometrial cancers, with patient HLA class II alleles. The most striking indication is that TCR-β J subgroup usage, in combination with particular patient HLA class II alleles, correlated with either better or worse outcomes for lung cancer. One combination, TCR-β J2 segment usage and the HLA-DRB1*1501 allele, correlated with a better survival rate for both lung and head and neck cancers. These results fill a gap in knowledge regarding the relevance of HLA typing to cancer and indicate that HLA typing, along with an indication of dominant TCR-β J usage among tissue-resident lymphocytes, can be useful for prognosis.


T cell receptor-β HLA class I and class II proteins Antigen presentation Cancer immune response The Cancer Genome Atlas 



Head and neck squamous carcinoma


Kidney and renal carcinoma


Lung adenocarcinoma


Ovarian cancer


The Cancer Genome Atlast


Uterine corpus and endometrial carcinoma



Authors would like to acknowledge the support of USF Research Computing and the taxpayers of the State of Florida. BMC was a recipient of a Bonati scholarship.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12026_2018_8990_MOESM1_ESM.pdf (6 mb)
ESM 1 (PDF 6142 kb)


  1. 1.
    Qin N, Wang C, Zhu M, Lu Q, Ma Z, Huang M, et al. Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer. Lung Cancer. 2017;112:169–75. Scholar
  2. 2.
    Gragnani L, Fognani E, De Re V, Libra M, Garozzo A, Caini P, et al. Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. Oncotarget. 2017;8(42):71528–35. Scholar
  3. 3.
    Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of productively rearranged TcR-alpha V-J sequences in TCGA exome files: implications for tumor immunoscoring and recovery of antitumor T-cells. Cancer Inform. 2016;15:23–8. Scholar
  4. 4.
    Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-beta VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immun Immunother. 2017;66(3):403–10. Scholar
  5. 5.
    Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother. 2017;13(3):501–6. Scholar
  6. 6.
    Tu YN, Tong WL, Samy MD, Yavorski JM, Kim M, Blanck G. Assessing microenvironment immunogenicity using tumor specimen exomes: co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression. Int J Cancer J Int du cancer. 2017;140:2568–76. Scholar
  7. 7.
    Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12):1109–12. Scholar
  8. 8.
    Xie C, Yeo ZX, Wong M, Piper J, Long T, Kirkness EF, et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc Natl Acad Sci U S A. 2017;114(30):8059–64. Scholar
  9. 9.
    Di Sante G, Tolusso B, Fedele AL, Gremese E, Alivernini S, Nicolo C, et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. EBioMedicine. 2015;2(12):2037–45. Scholar
  10. 10.
    Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046–53. Scholar
  11. 11.
    Miles JJ, Bulek AM, Cole DK, Gostick E, Schauenburg AJ, Dolton G, et al. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog. 2010;6(11):e1001198. Scholar
  12. 12.
    Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, et al. Identifying specificity groups in the T cell receptor repertoire. Nature. 2017;547(7661):94–8. Scholar
  13. 13.
    Quandt JA, Huh J, Baig M, Yao K, Ito N, Bryant M, et al. Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol. 2012;189(6):2897–908. Scholar
  14. 14.
    Klarenbeek PL, Doorenspleet ME, Esveldt RE, van Schaik BD, Lardy N, van Kampen AH, et al. Somatic variation of T-cell receptor genes strongly associate with HLA class restriction. PLoS One. 2015;10(10):e0140815. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Molecular Medicine, Morsani College of MedicineUniversity of South FloridaTampaUSA
  2. 2.Immunology ProgramH. Lee Moffitt Cancer and Research InstituteTampaUSA

Personalised recommendations